Liponex begins dosing in phase 1/ 2 trial of CRD5 cholesterol drug

By Angela McDaniels

Seattle, Sept. 7 - Liponex Inc. completed patient recruitment for the phase 1/ 2 clinical trial of its lead compound, CRD5, for the treatment of dyslipidemia and heart disease and began patient dosing, according to a company news release.

The single-blinded, dose-ranging trial is taking place at the Riverside Hospital in Ottawa in 50 dyslipidemic patients who will receive a placebo plus three different doses of the latest formulation of CRD5 in capsule form. The total treatment time following a dietary lead-in will be 12 weeks.

The primary endpoints for the trial are safety and an increase in serum high-density lipoprotein, also known as "good cholesterol," with decreases in triglyceride and low-density lipoprotein levels as secondary endpoints. Patient treatment is expected to last through the end of 2006, and the company plans to report results from the trial in the first quarter of 2007.

Liponex, an Ottawa, Ont.-based biopharmaceutical company, develops products that use high-density lipoprotein as a transport vehicle to remove excess cholesterol or other unwanted materials from the body and to deliver molecules to cells.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.